Gyros appoints Katherine Flagg as VP Sales North America

06-Feb-2009

The Swedish instrument company GyrosAB is pleased to announce the appointment of Katherine Flagg as its vice-president of sales for North America.

Katherine Flagg has extensive experience in the biotech supply industry. Her in-depth knowledge of the process involved in the development of protein therapeutics will be of significant value to Gyros as well as for researchers who employ Gyrolabworkstations to accelerate their drug development process.

Ms. Flagg has held key roles in sales at Pharmacia Biotech (now GE Healthcare), BioVeris/IGEN, ForteBio and most recently at BioScale. “Her track-record in our industry has earned her a solid reputation as someone who brings value to customers by helping them to identify and implement relevant new tools,” states Lars Eric Utterman, CEO of Gyros. “Katherine is also a strong motivator and mentor. Her skills in the management of sales, service and support are considered by many as highly effective and are much appreciated by both staff and customers. With the positive leadership she brings, our US operations will be well-equipped to serve our rapidly growing customer base of CROs, CMOs, pharmaceutical and biotech companies,” he concludes.


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.